Nicoletta Merli¹, Paolo Lissoni¹, Giuseppe Di Fede¹, Marco Tornasi¹, Dino Ceppodomo¹ and Carlo Pastore²*

¹Institute of Biological Medicine, Milan, Italy ²Sanatrix Clinic, Oncological Department, Rome, Italy

*Corresponding Author: Carlo Pastore, Sanatrix Clinic, Oncological Department, Rome, Italy.

Received: July 18, 2022; Published: September 29, 2022

Abstract

Lymphocytopenia is something that cancer patients present with very often. Lymphocyte deficiency appears to be correlated with a worse prognosis. This experimental study emphasises how the combination of melatonin and AHCC in appropriate dosages can help counteract lymphopenia.

Keywords: Melatonin; Cancer; Lymphocytopenia; AHCC

References

1. Hlubocky FJ., et al. “Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials”. Journal of Clinical Oncology 25 (2007): 548-554.
2. Reiter RJ. “Mechanisms of cancer inhibition by melatonin”. Journal of Pineal Research 37 (2004): 213-214.
3. Bartsch C and Bartsch H. “Melatonin in cancer patients and in tumor-bearing animals”. Advances in Experimental Medicine and Biology 467 (1999): 247-264.
4. Lissoni P. “The pineal gland as a centrai regulator of cytokine network”. Neuroendocrinology Letter 20 (1999): 343-349.
5. Pastore C. “Treatment of Platelet Deficiency in a Cohort of Patients by a Combination of Melatonin and 5-Methoxytryptamine". Acta Scientific Medical Sciences7 (2021): 66-67.
6. Maestroni GJM. “The immunoneuroendocrine raie of melatonin”. Journal of Pineal Research 14 (1993): 1-10.
7. Kuklina EM., et al. “Raie of melatonin in the regulation of differentiation of Tcell producing interleukin -17 (Th17)”. Bulletin of Experimental Biology and Medicine 160 (2016): 656-658.
8. Yang B., et al. “The raie of interleukin 17 in tumour proliferation, angiogenesis and metastasis”. Mediators of Inflammation (2014): 623759.
9. Lissoni P., et al. “Dose-dependency of antitumor effects of the pineal hormone melatonin in untreatable metastatic solid turnar patients”. International Journal of Immunology and Immunotherapy 1 (2018): 104-106.
10. Mills E., et al. “Melatonin in the treatment cancer: a systematic review of randomized contrailed trials and meta-analysis”. Journal of Pineal Research 39 (2005): 360-366.
11. Lissoni P., et al. “Five year-survival with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible far the only palliative therapy”. Research Journal of Oncology 2 (2018): 1-7.
12. Grimm EA., et al. “Lymphokine-activated killer celi phenomenon”. Journal of Experimental Medicine 155 (1982): 1823-1841.
13. Mantovani A., et al. “Cancer-related inflammation”. Nature 454 (2008): 436-444.
14. Gu L., et al. “Prognostic role of lymphocyte-to-monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis”. Oncotarget 3 (2016): 7876-7881.
15. Cao Z., et al. “Active hexose correlateci compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of the immune function in hepatoma 22 tumor-bearing mice”. Nutrition Research and Practice 9 (2015): 129-136.
16.  

Citation

Citation: Carlo Pastore., et al. “A Phase-2 Study of High-dose Melatonin in Association with Active Hexose-correlated Compound (NK-Life) in Advanced Cancer Patients with Persistent Lymphocytopenia".Acta Scientific Medical Sciences 6.10 (2022): 51-53.

Copyright

Copyright: © 2022 Carlo Pastore., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.